Zai Lab Ltd.
Latest From Zai Lab Ltd.
Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
- Medical Devices
- Therapeutic Areas
- Immune Disorders
- Respiratory, Pulmonary
- ZAI Laboratory Inc.
- Parent & Subsidiaries
- Zai Lab Ltd.
- Senior Management
Samantha Du, PhD, Chmn. & CEO
Billy Cho, CFO
Jonathan Wang, SVP, Head, Bus. Dev.
William Liang, Chief Commercial Officer
Tao Fu, Pres. & COO
- Contact Info
Zai Lab Ltd.
Phone: 21 6163 2588
4560 Jinke Rd., Jinchuang Plaza Bldg. 1
Pudong, Shanghai, 201210
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.